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Generating pluripotent stem cells directly from cells obtained from patients is one of the ultimate
goals in regenerative medicine. Two ‘‘reprogramming’’ strategies for the generation of pluripotent
stem cells from somatic cells have been studied extensively: nuclear transfer to oocytes and fusion
with ES cells. The recent demonstration that, in mouse, nuclear transfer into zygotes can also be ef-
fective if the recipient cells are arrested in mitosis provides an exciting new avenue for this type of
approach. Patient-specific pluripotent cells could potentially also be generated by the spontaneous
reprogramming of bone marrow cells, spermatogonial cells, and parthenogenetic embryos. A third
overall type of strategy arose from the demonstration that pluripotent stem (iPS) cells can be gener-
ated from mouse fibroblasts by the introduction of four transcription factors (Oct-3/4, Sox2, c-Myc,
and KLF4). Recent work has underlined the potential of this strategy by improving the efficiency of the
process and demonstrating that iPS cells can contribute to many different tissues in vivo, including
the germline. Taken together, these studies underscore the crucial roles of transcription factors and
chromatin remodeling in nuclear reprogramming.Embryonic stem (ES) cells are derived from the inner cell
mass (ICM) of blastocyst stage embryos, and they have
the unique capacity to proliferate extensively while main-
taining pluripotency (Evans and Kaufman, 1981; Martin,
1981). ES cell lines can also be generated from human
blastocyst embryos (Thomson et al., 1998) and are con-
sidered promising donor sources for cell transplantation
therapies for diseases such as juvenile diabetes, Parkin-
son’s disease, and heart failure. However, as for organ
transplants, tissue rejection remains a significant concern
for ES cell transplantation. Another concern is the use of
human embryos. One possible means to avoid these is-
sues is by reprogramming the nuclei of differentiated cells
to ES cell-like, pluripotent cells.
Currently, three methods have been reported to induce
pluripotency artificially in mouse somatic cells (Figure 1).
ES-like cells can also be established by long-term culture
of bone marrow cells, and pluripotent stem cells can be
generated from adult germ cells, either by the in vitro
culture of spermatogonial cells or by the parthenogenesis
of unfertilized eggs. This review discusses the potential of
these strategies to generate tailor-made pluripotent stem
cells and the role of transcription factors in the reprogram-
ming process.
Reprogramming by Nuclear Transfer
Successful nuclear transfer was first reported in 1952 by
Briggs and King, who showed that nuclei from blastula
stage embryos into enucleated Rana pipiens eggs re-sulted in normal hatched tadpoles (Briggs and King,
1952). Gurdon and colleagues then succeeded in produc-
ing fertile adult frogs by transferring tadpole intestinal
cell nuclei into enucleated Xenopus laevis eggs in 1996
(reviewed in Gurdon and Byrne [2003]). However, when
they transferred the nuclei from adult somatic cells, ani-
mals developed to the tadpole but thereafter did not
develop further toward the adult stage.
Due to the smaller cell size, nuclear transfer in mammals
is more technically demanding. In 1975, Bromhall re-
ported development to the morula stage following the nu-
clear transfer of rabbit morula cell nuclei into enucleated
rabbit eggs, albeit with low efficiency (Bromhall, 1975).
The successful nuclear transfer of embryonic donor cell
nuclei, which produced adult progeny, was subsequently
reported in various mammalian species (Gurdon and
Byrne, 2003). However, it proved difficult to generate
cloned animals by nuclear transfer from differentiated
cells into eggs.
A breakthrough came in 1996, when Wilmut and col-
leagues produced an adult sheep, famously known as
‘‘Dolly,’’ using nuclei derived from follicle cells (Wilmut
et al., 1997). Subsequently, somatic cloning was success-
fully performed in other species, such as the cow, mouse,
goat, pig, cat, and rabbit (Gurdon and Byrne, 2003).
Furthermore, Jaenisch and colleagues generated mice
from B lymphocytes that had undergone immunoglobulin
rearrangement (Hochedlinger and Jaenisch, 2002). How-
ever, this process required a two-step strategy to obtainCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 39
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ReviewFigure 1. Currently Available Methods to Generate Pluripotent Stem Cells from Adult Somatic or Germ Cells
In mouse models, three methods have been reported to generate pluripotent stem cells from somatic cells: nuclear transfer, fusion, and forced
expression of defined factors. Also reported is the generation of chimera-competent pluripotent stem cells after the long-term culture of bone marrow
cells. In addition, pluripotent stem cells can be established from mouse adult germ cells: multipotent GS cells and parthenogenetic ES cells.mice from the terminally differentiated lymphocytes; ES
cells were derived from cloned embryos, and mice were
then made from those ES cells. The same group observed
the highest success rates for cloned animals from ES cells
and neural stem cells (Blelloch et al., 2006). Therefore, a re-
verse correlation between the degree of cell differentiation
and the reprogramming efficiency seems to be general
phenomena in mammals and amphibians.
In contrast to the extremely low efficiency of obtaining
cloned animals, ES cells can be generated from cloned
mouse blastocysts with comparable efficiency to those
from normal embryos (Wakayama et al., 2001). These
nuclear transfer (nt) ES cells might provide a means of
avoiding immune rejection after transplantation therapy
(Hochedlinger and Jaenisch, 2003), if applicable in human.
In 2005, a group in Korea reported that they had success-
fully generated ntES cells from the skin cells of patients
suffering from spinal cord injury and juvenile diabetes
(Hwang et al., 2004, 2005). However, their data were later
shown to be fabricated, and in fact, they were unable to
generate a single ntES cell line from more than 2000
human eggs, thus indicating that generating ntES cells in
humans is technically demanding.
A significant issue when considering the potential of
nuclear transfer strategies for generating patient-specific
human ES cell lines is the availability of human oocytes.
However, exciting new work in mouse suggests that it
may be possible to devise new strategies that avoid the40 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.oocyte requirement. Egli et al. (2007) have found that it
is possible to generate pluripotent cells by nuclear transfer
using adult somatic cells as donors and zygotes as recip-
ients. Their new protocol involves arresting the recipient
zygote in mitosis using drug treatment, removing its chro-
mosomes and replacing them with donor-derived mitotic
chromosomes. The mitotic arrest is key, because transfer
to interphase zygotes is not effective for donor nuclei
beyond the four-cell embryo stage. Using this method,
Egli et al. were able to produce embryonic stem cell lines
from embryonic and somatic donor cells, and they dem-
onstrated full reprogramming by generating chimeric
embryos with germline transmission. Currently, this
method has only been demonstrated with mouse zygotes.
However, it does raise the possibility that discarded hu-
man IVF embryos could potentially be used as recipients
for human ntES cell derivation instead of oocytes and
even, hypothetically, that mitotic cytoplasm from current
hES cell lines might have more effective reprogramming
activity than the previously tested interphase extracts.
Several proteins have been shown to play roles in re-
programming in frog oocytes, and their identities may
well give clues to the overall requirements for reprogram-
ming in other species as well. These include ISWI, which is
involved in protein exchange between the transferred nu-
cleus and the oocyte cytoplasm (Kikyo et al., 2000), and
Brg1, which is required for the activation of Oct-3/4, a tran-
scription factor specifically expressed in undifferentiated
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ReviewFigure 2. Nanog-Mediated Enhancement of Reprogramming by Fusion with ES Cells
Nanog-overexpressing mouse ES cells showed a marked increase in reprogramming activity after fusion with neural stem (NS) cells. The forced
expression of Nanog in NS cells was found to be less effective.cells (Hansis et al., 2004). Both ISWI and Brg1 are chroma-
tin remodeling ATPases, thus indicating the crucial role of
chromatin remodeling in nuclear reprogramming. In addi-
tion, the germ cell proteins FRGY2a and FRGY2b revers-
ibly disassemble somatic nucleoli in egg cytoplasm
(Gonda et al., 2003), whereas the egg protein nucleophos-
min may be involved in chromatin decondensation (Tam-
ada et al., 2006). In devising their new strategy, Egli
et al. (2007) reasoned that one difference between
oocytes and zygotic cells as potential recipients could be
that required factors such as these might become local-
ized to the nucleus during interphase. However, during
mitosis the factors could be released and thus available
to contribute to reprogramming.
Reprogramming by Fusion with ES Cells
In 1976, Miller and Ruddle demonstrated thymocytes
fused with embryonic carcinoma (EC) cells to show pluri-
potency (Miller and Ruddle, 1976), and similar results were
later obtained by electrofusion with mouse ES cells (Tada
et al., 2001). Transplantation of these cells into nude mice
results in formation of teratomas consisting of various
tissues from all three germ layers, confirming the pluripo-
tency of these cells. More recently, reprogramming by
fusion with human ES cells was reported (Cowan et al.,
2005; Yu et al., 2006).
Whether somatic genomes are fully reprogrammed by
fusion remains to be resolved. In thymocyte-ES hybrid
cells, the promoter regions of several genes, including
Oct-3/4, in the thymocyte genome acquired ES-like epige-
netic status, including histone acetylation and methylation
(Kimura et al., 2004). Therefore, at least a part of the
somatic genome is reprogrammed by fusion. Genome-
wide gene expression analyses and chromatin immuno-precipitation analyses will reveal the extent to which
somatic genome is reprogrammed by fusion with ES cells.
Tada and colleagues recently developed a system to
remove a selected chromosome from hybrid cells
(Matsumura et al., 2007). They showed that removal of
ES cell-derived chromosomes containing Nanog, which
encodes a transcription factor important for pluripotency
(Chambers et al., 2003; Mitsui et al., 2003), did not affect
the pluripotency of hybrid cells. The final proof of com-
plete reprogramming would be to show that such hybrid
cells remain pluripotent even after removal of all of the
ES cell-derived chromosomes.
Rejection upon implantation remains an issue with hy-
brid cells because of the ES cell-derived chromosomes.
Although the selective elimination of specific chromo-
somes (Matsumura et al., 2007) is an important step to cir-
cumvent this problem, removing all of the ES cell-derived
chromosomes would be technically challenging. Alterna-
tively, ES cell-derived chromosomes carrying the major
histocompatibility complex (MHC) loci could be removed
selectively to avoid, or at least reduce, rejection reactions.
This possibility should be experimentally investigated.
Other groups have attempted to reprogram somatic cells
with ES cell extracts (Taranger et al., 2005).
Little is known about the molecular mechanisms under-
lying reprogramming by fusion with ES cells. The factors
responsible may reside in the nucleus (Do and Scholer,
2004) or in cytoplasm (Strelchenko et al., 2006). Smith
and colleagues observed marked increase in reprog-
rammed cell colonies when they fused neural stem cells
with ES cells that overexpress the transcription factor
Nanog (Figure 2) (Silva et al., 2006). Nanog is a homeobox
transcription factor specifically expressed in early mouse
embryos and ES cells (Chambers et al., 2003; MitsuiCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 41
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enables them to undergo self-renewal in the absence of
leukemia inhibitory factor (LIF) (Chambers et al., 2003;
Mitsui et al., 2003). Similarly, overexpression of Nanog in
human ES cells enabled growth without feeder cells
(Darr et al., 2006). Nanog null embryos show disorganiza-
tion of the extraembryonic tissues at E5.5, with no discern-
ible epiblast or primitive ectoderm (Mitsui et al., 2003)
(Table 1). ES cells lacking Nanog can be derived, but
they tend to differentiate spontaneously into extraembry-
onic endoderm lineages even in the presence of LIF.
Another group reported that even heterozygous Nanog
mutant ES cells were unstable and susceptible to sponta-
neous differentiation (Hatano et al., 2005). RNAi-mediated
knockdown of Nanog led to differentiation in both
mouse (Ivanova et al., 2006) and human (Zaehres et al.,
2005) ES cells. These data underscore the crucial role
that Nanog plays in the induction and maintenance of
pluripotency.
Spontaneous Reprogramming by Culture
ES cells do not exist physiologically. They are ‘‘trans-
formed’’ and ‘‘reprogrammed’’ during the course of
long-term culture of ICM. Similarly, pluripotent embryonic
germ (EG) cells can be generated by long-term culture of
primordial germ cells (PGC) (Matsui et al., 1992). There-
fore, it might be possible to obtain pluripotent stem cells
by culturing other types of cells. In fact, Verfaillie and as-
sociates reported the development of pluripotent stem
cells after the prolonged culture of bone marrow-derived
cells (Jiang et al., 2002). They designated these cells multi-
potent adult progenitor cells (MAPCs). MAPCs are differ-
ent from ES cells in that they require a low serum concen-
tration and have to be maintained at a low density.
Nevertheless, MAPCs can differentiate into various types
of cells in vitro, and in one case, a single MAPC injected
into a mouse blastocyst contributed to mouse develop-
ment and formed chimeras. However, definitively proving
the generality and reproducibility of MAPCs still awaits
further experiments by other laboratories.
Shinohara and associates demonstrated that pluripo-
tent stem cells can be generated during the course of
culture of germline stem (GS) cells from neonate mouse
testes, which they designated multipotent germline stem
(mGS) cells (Kanatsu-Shinohara et al., 2004). While the
culture conditions of GS cells are different from those of
ES cells, mGS cells are maintained with ES cell culture
condition. mGS cells are similar to ES cells in morphology,
proliferation, and teratoma formation and are even com-
petent to form germline chimeras. The efficiency of mGS
cell establishment is extremely low and requires GS cells
from more than 30 testes. The efficiency may increase
by the loss of p53 function. Germline competent pluripo-
tent stem cells were also generated from adult mouse
testes, which were designated multipotent adult germline
stem (maGS) cells (Guan et al., 2006). Male-specific
imprints may result in an impaired differentiation ability
and transformation phenotype (Hernandez et al., 2003).
Although mGS cells showed a different imprinting pattern42 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.from GS cells and chimeric mice from mGS cells seem to
be normal (Kanatsu-Shinohara et al., 2004), long-term
observations are required to examine the tumorigenicity
of mGS cell-derived differentiated cells.
Reprogramming from spermatogonial stem cells can-
not apply to females. As an alternative, however, histo-
compatible ES cells can also be generated by partheno-
genesis. Since mammalian embryonic development
requires paternal gene expression, parthenogenetic em-
bryos die at early developmental stages after implanta-
tion. However, parthenogenetic ES cells have been suc-
cessfully obtained in mice and primates that showed
pluripotency (Allen et al., 1994; Cibelli et al., 2002). Most
of the parthenogenetic ES cells, however, show a loss of
heterozygosity in the MHC and thus may be rejected by
natural killer (NK) cells that recognize the lack of one set
of histocompatibility antigens. Daley and colleagues
developed methods to maintain both of the maternal
MHC loci in mouse parthenogenetic ES cells (Kim et al.,
2007). As with mGS cells, imprinting remains a concern
with parthenogenetic ES cells, since female-specific
imprinting is associated with premature senescence in
fibroblasts (Hernandez et al., 2003).
Reprogramming by Defined Factors
Successful reprogramming of somatic cells by fusion with
ES cells indicates that ES cells have factors that induce
pluripotency. It seemed likely that these pluripotency-
inducing factors also play important roles in the mainte-
nance of pluripotency. Based on this hypothesis, 24 differ-
ent candidate factors were tested for their ability to induce
pluripotency. This analysis led to the demonstration that
retrovirus-mediated introduction of four transcription
factors (Oct-3/4, Sox2, c-Myc, and KLF4) into mouse
embryonic or adult fibroblasts and selection for the
expression of Fbx15, a target of Oct-3/4 and Sox2,
resulted in the generation of induced pluripotent stem
(iPS) cells, which are similar to ES cells in morphology,
proliferation, and teratoma formation (Takahashi and
Yamanaka, 2006). Introduction of the three factors
excluding Sox2 results in cells somewhat similar to ES
cells in morphology and proliferation but lacking pluripo-
tency. Fbx15-selected iPS cells are, however, significantly
different from ES cells in gene expression and DNA
methylation patterns. When transplanted into blastocysts,
iPS cells only give rise to chimeric embryos, but not
adult or germline competent chimeras. These data
indicate that reprogramming in Fbx15-selected iPS cells
is incomplete.
Very recently, however, a significant improvement has
been demonstrated (Maherali et al., 2007; Okita et al.,
2007; Wernig et al., 2007). Three groups generated iPS
cells competent for adult and germline chimeras by using
a more stringent selection marker, Nanog. One also
demonstrated germline transmission to progeny mice
(Okita et al., 2007). Although both Fbx15 and Nanog are
targets of Oct-3/4 and Sox2, the former is dispensable
for pluripotency, while the latter plays crucial roles.
Nanog-selected iPS cells are almost indistinguishable
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Knockout ES Cells Knockout Embryos Overexpression in ES Cells
Oct-3/4 Cannot be established No epiblast Induces differentiation
Niwa et al., 2000 Nichols et al., 1998 Niwa et al., 2000
Sox2 Cannot be established No epiblast Does not induce differentiation
Masui et al., 2007 Avilion et al., 2003 Does not induce LIF independency
M. Nakagawa and S.Y., unpublished data
c-Myc Can be established Normal epiblast Does not induce differentiation
Normal self-renewal Induces LIF independency
Davis et al., 1993 Davis et al., 1993 Cartwright et al., 2005
KLF4 Not reported Normal epiblast Does not induce differentiation
Katz et al., 2002 Induces LIF independency
Y. Tokuzawa, M. Nakagawa, and S.Y., unpublished data
Nanog Can be established No epiblast Does not induce differentiation
Spontaneous differentiation Induces LIF independency
Mitsui et al., 2003 Mitsui et al., 2003 Chambers et al., 2003; Mitsui et al., 2003from ES cells in global gene expression (Okita et al., 2007),
DNA methylation, and histone modification (Maherali
et al., 2007; Wernig et al., 2007). Female Nanog-selected
iPS cells showed reactivation of a somatically silenced X
chromosome and underwent random X inactivation
upon differentiation (Maherali et al., 2007). Oct-3/4 can
also be used as a stringent selection marker for iPS cell
induction (Wernig et al., 2007). These data demonstrated
that full reprogramming can be achieved by expression
of the four factors and using an appropriate selection
procedure.
The Four Factors
Oct-3/4
Oct-3/4 was identified as a novel Oct family protein specif-
ically expressed in EC cells, early embryos, and germ cells
(Okamoto et al., 1990; Rosner et al., 1990; Scholer et al.,
1990). The Oct family transcription factors contain the
POU domain, an 150 amino acid sequence conserved
among Pit-l, Oct-1, Oct-2, and uric-86. Oct-3/4 and other
POU proteins bind to the octamer sequence (ATTA/
TGCAT). Expression of Oct-3/4 is restricted in the blasto-
meres of the developing mouse embryo, the ICM of
blastocysts, the epiblast, and germ cells. It is also ex-
pressed in pluripotent stem cells, including ES cells, EG
cells, EC cells, and mGS cells.
Oct-3/4 null embryos die in utero during the peri-
implantation stages of development (Nichols et al., 1998).
Although these embryos are able to reach the blastocyst
stage, in vitro culture of the ICM of homozygous mutant
blastocysts produces only trophoblast lineages (Table
1). ES cells can not be derived from Oct-3/4 null blasto-
cysts (Table 1). Suppression ofOct-3/4 resulted in sponta-
neous differentiation into the trophoblast lineages in both
mouse (Niwa et al., 2000) and human ES cells (Zaehreset al., 2005). These data demonstrate the essential roles
of Oct-3/4 in the maintenance of pluripotency.
Oct-3/4 also plays important roles in promoting differ-
entiation. Only a 50% increase in the Oct-3/4 protein in
mouse ES cells resulted in spontaneous differentiation
into primitive endoderm and mesoderm (Niwa et al.,
2000), which is consistent with the transient increase in
Oct-3/4 expression during the initial stage of primitive
endoderm differentiation from ICM (Table 1). Oct-3/4
also plays a role in the neural (Shimozaki et al., 2003)
and cardiac (Zeineddine et al., 2006) differentiation from
mouse ES cells. Hence, the level of Oct-3/4 expression
is an important determinant of the cell fate in mouse
ES cells.
Jaenisch and associates showed that activation of Oct-
3/4 in gastric epithelial tissues results in dysplastic growth
that is dependent on continuous transgene expression
(Hochedlinger et al., 2005). Dysplastic lesions show an
expansion of progenitor cells and an increased b-catenin
transcriptional activity. In the intestine, Oct-3/4 expres-
sion causes dysplasia by inhibiting cellular differentiation.
These data indicate that specific adult progenitors may re-
main competent to respond to key embryonic signals, and
they might also be a driving force in tumorigenesis.
Sox2
Sox2 was identified as a Sox (SRY-related HMG box)
protein expressed in EC cells (Yuan et al., 1995). The
high mobility group (HMG) domain is a DNA binding
domain conserved in abundant chromosomal proteins
including HMG1 and HMG2, which bind DNA with little
or no sequence specificity, and in sequence-specific tran-
scription factors, including SRY, SOX, and LEF-1. All
SOX factors appear to recognize a similar binding motif,
A/TA/TCAAA/TG. Like Oct-3/4, Sox2 also marks the
pluripotent lineage of the early mouse embryo; it isCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 43
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Oct-3/4, however, Sox2 is also expressed by the multipo-
tential cells of the extraembryonic ectoderm (Avilion et al.,
2003). In addition, Sox2 expression is associated with
uncommitted dividing stem and precursor cells of the
developing central nervous system (CNS), and it can be
used to isolate such cells (Li et al., 1998; Zappone et al.,
2000).
Sox2 null embryos die at the time of implantation due to
a failure of epiblast (primitive ectoderm) development
(Avilion et al., 2003). Homozygous mutant blastocysts
appear morphologically normal, but undifferentiated cells
fail to proliferate when blastocysts are cultured in vitro,
and only trophectoderm and primitive endoderm-like cells
are produced (Table 1). The deletion of Sox2 in ES cells
results in trophectoderm differentiation (Masui et al.,
2007). Therefore, Sox2, like Oct-3/4, is essential for the
maintenance of pluripotency.
Sox proteins, in general, regulate their target genes by
associating with specific partner factors (Kamachi et al.,
2000; Wilson and Koopman, 2002). Sox2 forms a hetero-
dimer with Oct-3/4 and synergistically regulates Fgf4
(Yuan et al., 1995), UTF1 (Nishimoto et al., 2003), and
Fbx15 (Tokuzawa et al., 2003). In addition, similar coregu-
lation by Sox2 and Oct-3/4 has been reported in the
regulation of Sox2 and Oct-3/4 themselves (Chew et al.,
2005; Okumura-Nakanishi et al., 2005; Tomioka et al.,
2002), as well as Nanog (Kuroda et al., 2005; Rodda
et al., 2005). Genome-wide chromatin immunoprecipita-
tion analyses demonstrated that Oct-3/4, Sox2, and
Nanog share many target genes in both mouse and human
ES cells (Boyer et al., 2005; Loh et al., 2006). Surprisingly,
Sox2 deletion in mouse ES cells is rescued by the cDNA
introduction of not only Sox2 but also Oct-3/4, thus
suggesting that the primary function of Sox2 might be to
maintain Oct-3/4 expression (Masui et al., 2007). The
authors speculated that the expression of Oct-Sox target
genes, such as Fgf4 and UTF1, can be maintained by
other Sox family proteins.
c-Myc
c-Myc is one of the first proto-oncogenes found in human
cancers (Dalla-Favera et al., 1982). The N terminus of Myc
binds to several proteins, including TRRAP, which are
components of the TIP60 and GCN5 histone acetyltrans-
ferase complexes, and TIP48 and TIP49, which contain
ATPase domains (Adhikary and Eilers, 2005). The C termi-
nus of the Myc protein contains the basic region/helix-
loop-helix/leucine zipper (BR/HLH/LZ) domain, through
which Myc binds to a partner protein, Max. The Myc-
Max dimers bind to a DNA sequence (CACA/GTG), which
is a subset of the general E box sequence (CANNTG) that
is bound by all bHLH proteins. In addition to binding to
DNA, the C terminus of Myc is also involved in transactiva-
tion through binding to CBP and p300, which have histone
acetylase activities.
Mouse embryos homozygous for a c-Myc deletion die
between 9.5 and 10.5 days of gestation (Davis et al.,
1993). Pathologic abnormalities include the heart, pericar-
dium, neural tube, and delay or failure in turning of the em-44 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.bryo. The lethality of c-Myc/ embryos is also associated
with profound defects in vasculogenesis and primitive
erythropoiesis (Baudino et al., 2002). In addition,
c-Myc/ ES cells are defective in vascular differentiation.
However, earlier-stage embryos are apparently normal
despite the deficiency of c-Myc, and c-Myc/ ES cells
show a normal proliferation and self-renewal (Table 1). In
contrast, the dominant-negative form of c-Myc induces
differentiation in mouse ES cells (Cartwright et al., 2005),
thus suggesting that the c-Myc deficiency might be
compensated by the related proteins N-Myc and L-Myc.
The most surprising new finding is that there are as
many as 25,000 Myc binding sites in vivo in the human
genome (Cawley et al., 2004; Fernandez et al., 2003; Li
et al., 2003). These studies revealed that only a minority
portion of the in vivo binding sites of Myc-Max have the
consensus CACA/GTG sequence. The direct binding of
the Myc-Max dimer to noncanonical sequences is ob-
served in the human Werner syndrome gene, WRN
(Grandori et al., 2003). Alternatively, the Myc-Max dimer
is recruited to nonconsensus binding sites through an
interaction with other transcription factors, such as Miz1
(Peukert et al., 1997). By binding to numerous sites in
genome, c-Myc may modify the chromatin structure
(Knoepfler et al., 2006) and regulate the expression of
noncoding RNAs (O’Donnell et al., 2005).
KLF4
KLF4 belongs to Kru¨ppel-like factors (KLFs), zinc-finger
proteins that contain amino acid sequences resembling
those of the Drosophila embryonic pattern regulator
Kru¨ppel (Schuh et al., 1986). KLF4 is highly expressed in
differentiated, postmitotic epithelial cells of the skin and
the gastrointestinal tract. KLF4 is expressed in fibroblasts
including MEF and NIH3T3 cells (Garrett-Sinha et al.,
1996; Shields et al., 1996). Shields et al. found that, in
NIH3T3 cells, KLF4 mRNA is found in high levels in cells
during growth arrest and is nearly undetectable in cells
that are in the exponential phase of proliferation (Shields
et al., 1996). In addition, KLF4 is highly expressed in undif-
ferentiated mouse ES cells (Y. Tokuzawa, M. Nakagawa,
and S.Y., unpublished data).
KLF4 can function both as a tumor suppressor and an
oncogene. In cultured cells, the forced expression of
KLF4 results in the inhibition of DNA synthesis and cell
cycle progression (Chen et al., 2001; Shields et al., 1996).
KLF4 null embryos develop normally (Table 1), but new-
born mice die within 15 hr and show an impaired differen-
tiation in the skin (Segre et al., 1999) and in the colon (Katz
et al., 2002), thus indicating that it plays a crucial role as
a switch from proliferation to differentiation. A conditional
knockout mouse model suggests that KLF4 plays a role
as a tumor suppressor in gastrointestinal cancers (Katz
et al., 2005). KLF4, however, is overexpressed in squa-
mous cell carcinomas and breast cancers (Foster et al.,
2000; Foster et al., 1999). Moreover, the induction of
KLF4 in basal keratinocytes blocks the proliferation-
differentiation switch and initiates squamous epithelial dys-
plasia (Foster et al., 2005). Therefore, KLF4 is associated
with both tumor suppression and oncogenesis.
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Factors in the Induction of iPS Cells
Pluripotent stem cells are immortal and have
open and active chromatin structure. It is likely
that c-Myc induces these two important prop-
erties. However, c-Myc also induces apoptosis
and senescence, which are probably sup-
pressed by KLF4. Oct-3/4 probably changes
the cell fate from tumor cells to ES-like cells.
To establish pluripotency, Sox2 is also re-
quired.Recently, the molecular mechanisms underlying the
dual functions of KLF4 were partially elucidated (Rowland
et al., 2005). They showed that ectopic expression of KLF4
suppresses cell proliferation, but ablation of only one of its
target genes, p21, is sufficient to rescue the cytostatic
effect of KLF4. In p21 null cells, KLF4 promotes cell prolif-
eration by downregulating p53 (Rowland et al., 2005).
Therefore, p21 may function as a switch that determines
the outcome of KLF4 signaling (Rowland and Peeper,
2006).
The inactivation of STAT3 in mouse ES cells markedly
decreases KLF4 expression, and forced expression of
KLF4 enables LIF-independent self-renewal (Table 1;
Y. Tokuzawa, M. Nakagawa, and S.Y., unpublished data).
Another group also reported a positive effect of KLF4 in
self-renewal of mouse ES cells (Li et al., 2005). In addition,
KLF4 cooperates with Oct-3/4 and Sox2 to activate the
Lefty1 core promoter in mouse ES cells (Nakatake et al.,
2006).
How Do the Four Factors Induce Pluripotent
Stem Cells?
ES cells and other pluripotent stem cells are similar to
tumor cells in many aspects. ES cells are immortal and
proliferate rapidly. They form tumors (teratomas) when
transplanted into immune-deficient mice. Pluripotent
stem cells are, in a sense, reversibly ‘‘transformed’’ cells.
The transformation takes place during the course of
in vitro culture or in their original embryonic cells (ICM
for ES cells and PGC for EG cells). Some genes, such as
E-Ras (Takahashi et al., 2003), are activated in this
process, making ES cells and EG cells distinct from their
originating cells.
Taking this into account, it makes sense that the induc-
tion of pluripotent stem cells (iPS cells) from somatic cells
also requires transformation by the two tumor-associated
gene products, c-Myc and KLF4 (Figure 3). The Myc pro-
tein can elicit various aspects of transformation (Adhikary
and Eilers, 2005). However, it also elicits p53-dependent
apoptosis in primary fibroblasts. KLF4 might therefore
be required to suppress p53 and c-Myc-induced apopto-
sis (Rowland et al., 2005). KLF4, in turn, activates p21 andsuppresses proliferation. c-Myc can alleviate this cyto-
static effect of KLF4 by suppressing p21. Thus, the
balance between c-Myc and KLF4 might play a critical
role in the transformation process in iPS cells.
It is likely that the function of c-Myc is not confined
to the induction of cellular transformation. Pluripotent
stem cells have open and active chromatin structures
(Meshorer et al., 2006). Myc proteins probably loosen
the chromatin structure of somatic cells by binding to
numerous sites throughout the genome and by recruiting
multiple histone acetylase complexes (Knoepfler et al.,
2006). Consistent with this model, even partially reprog-
rammed Fbx15-iPS cells show hyperacetylated histones
in the promoter regions of several ES cell-specific genes
(Takahashi and Yamanaka, 2006).
Forced expression of c-Myc and KLF4 alone would
result in the generation of tumor cells, but not pluripotent
stem cells. It is likely that Oct-3/4 directs the cell fate
away from tumor cells toward ES-like cells. The effects
of c-Myc on chromatin structure should enable Oct-3/4
to activate or suppress appropriate target genes. Oct-3/4,
however, is not sufficient to induce pluripotency. Sox2
is also required to synergistically activate multiple target
genes. KLF4 may also function as a cofactor of Oct-3/4
and Sox2 (Nakatake et al., 2006). The finding that
a Sox2 deletion in mouse ES cells can be rescued by an
Oct-3/4 transgene (Masui et al., 2007) seems to conflict
with this finding. However, it is possible that maintenance
of pluripotency can be achieved by other Sox proteins that
exist at low levels in ES cells, while the induction of pluri-
potency requires much higher amounts of Sox proteins.
Another key issue is the low efficiency of iPS cell induc-
tion. Less that 1% of the cells that have incorporated the
four retroviruses can become iPS cells. One possible
explanation is that the origin of iPS cells in fact originate
from tissue stem or progenitor cells coexisting in the fibro-
blast culture. An observation consistent with this possibil-
ity is that ectopic expression of Oct-3/4 in the stomach
and intestine block the differentiation of progenitor cells
(Hochedlinger et al., 2005). Another possibility is that, in
addition to the four factors, another factor or factors also
need to be activated by retroviral insertion. CandidatesCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 45
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Requirement of
Embryos or
Donor Oocytes
Report in
Human
Chromosome
Content Imprinting Reference
Nuclear transfer Yes No Normal diploid;
no gene transfer
Normal? Rideout et al., 2000
Fusion with ES cells Yes Yes Tetraploid Normal? Tada et al., 2001
iPS cells No No Retroviral integration Normal? Takahashi and Yamanaka, 2006
MAPC No Yes Normal diploid;
no gene transfer
Normal? Jiang et al., 2002
mGS cells No No Normal diploid;
no gene transfer
Different
from ES cells
Kanatsu-Shinohara et al., 2004
Parthenogenetic
ES cells
No No Normal diploid;
no gene transfer
Female specific Allen et al., 1994for such factors include the polycomb proteins, which play
a critical role in the maintenance of pluripotency (Boyer
et al., 2006), and chromatin remodeling factors such as
ISWI (Kikyo et al., 2000) and Brg1 (Hansis et al., 2004),
which might be involved in nuclear reprogramming in
oocytes. The identification of the missing factor(s) may en-
able more efficient and retrovirus-free generation of iPS
cells. Alternatively, iPS cell induction may depend on
specific amounts and patterns of the expression of the
four factors, which are achieved by chance in a small
proportion of the transfected cells. For example, excess
Oct-3/4 is detrimental to pluripotency (Niwa et al., 2000).
In addition, the balance between c-Myc and KLF4 may
also be a crucial factor.
Conclusion
This review has provided an overview of the currently
available methods to generate pluripotent stem cells
from adult somatic or germ cells. Each method has advan-
tages as well as disadvantages over other methods (Table
2). Nuclear transfer and iPS cells can induce nearly com-
plete reprogramming. In addition, iPS cells are an appeal-
ing option, as no embryos or oocytes are required for their
generation. However, only fusion with ES cells has been
achieved with human cells. Tumorigenicity is a concern
for all methods. This issue is especially pertinent for iPS
cells, which use retroviruses, and fusion with ES cells,
which results in tetraploid cells. In fact, we found that re-
activation of c-Myc retrovirus causes tumors in Nanog-
iPS cell-derived mice (Okita et al., 2007). At this time it is
premature to discuss which method will ultimately be
most appropriate for clinical use. It is important to pro-
mote thorough and careful basic research on all the
methods. Eventually, such studies could potentially even
lead to the development of a new, unified technology. It
is also important to understand the molecular mecha-
nisms underlying nuclear reprogramming and pluripo-
tency. The factors focused on in this review are likely to
play critical roles, but it seems likely that other transcrip-
tion factors and chromatin-related factors also make
important contributions.46 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.ACKNOWLEDGMENTS
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